Duchenne News Tags: Roche

April 21, 2026
On April 16, 2026, Roche announced it will initiate a new, global, pivotal Phase III study for Elevidys™ (delandistrogene moxeparvovec), the first approved gene therapy to treat the underlying cause...
February 20, 2026
On February 20, 2026, Roche shared an important update in a community letter regarding their work in bone health in Duchenne and the SHIELD DMD study. Read more by visiting...

Jett Foundation’s Silver Soirée
Thursday, June 11, 2026 | 5:30PM
Granite Links | Quincy, MA